Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 444 across all filing types
Latest filing 2026-05-29 Share Issue/Capital Cha…
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
Share Issue/Capital Change Classification · 82% confidence The document is a mandatory disclosure under the EU Market Abuse Regulation announcing the issuance of 5,000 new Class B shares upon exercise of stock options and providing updated total share and vote counts. This is an announcement of a share issue and capital structure change, matching Share Issue/Capital Change (SHA).
2026-05-29 English
Antal aktier och röster i BioArctic AB (publ) per den 29 maj 2026
Share Issue/Capital Change Classification · 94% confidence The text is a press release disclosing that the company issued 5,000 new B-shares under its 2019/2028 option program and reports the updated total number of shares and votes. This is a capital change announcement regarding a share issuance. Therefore it fits the “Share Issue/Capital Change” category (SHA).
2026-05-29 Swedish
Bulletin from the Annual General Meeting in BioArctic AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release issued immediately after the Annual General Meeting, summarizing all resolutions adopted (dividend, board elections, auditor appointment, share issue authorizations, incentive program, remuneration guidelines, etc.). It does not contain the full AGM slide deck nor the detailed financial statements themselves, but rather the official outcomes of the shareholder votes. This matches the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-05-28 English
Kommuniké från årsstämma i BioArctic AB (publ)
AGM Information Classification · 94% confidence The document is a press release titled “Kommuniké från årsstämma” summarizing the resolutions and decisions made at BioArctic AB’s Annual General Meeting, including election of board members, approval of financial statements, dividend, auditor appointment, authorizations and incentive programs. It is not the full annual report or a Q&A transcript but the official AGM communique, fitting the AGM Information category.
2026-05-28 Swedish
BioArctics partner Eisai presenterar simulering av potentiell framtida försäljning av Leqembi® vid sin kapitalmarknadsdag (Investor Relations Day)
Regulatory Filings Classification · 85% confidence The document is a press release announcing that BioArctic’s partner Eisai has published an investor presentation containing a sales simulation for Leqembi. It does not contain substantive financial statements, management discussion, or an actual investor deck; instead, it provides regulatory-required disclosure and a link to the partner’s presentation. It is a miscellaneous regulatory announcement rather than an earnings release, report, or call transcript, so it should be classified under Regulatory Filings (RNS).
2026-05-25 Swedish
BioArctic’s partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day
Report Publication Announcement Classification · 91% confidence The document is a press release announcing that BioArctic’s partner Eisai has published a presentation (Investor Relations Day sales simulation) with a link to the presentation. It does not contain substantive financial statements or data itself, but merely directs readers to a published report. Under the “Menu vs Meal” rule, this is a report publication announcement rather than an actual investor presentation file or financial report.
2026-05-25 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.